Gentamicin is an aminoglycoside antibiotic effective against aerobic gram-negative bacteria and is also used in veterinary medicine, particularly in the swine and bovine industries. However, no gentamicin product is currently approved for treating equine diseases in Korea. The present study aims to examine the time-dependent residue of gentamicin in horses after intravenous injection (IV) via jugular vein. The test product was injected at 6.6 mg/kg BW via jugular vein in nine horses. Blood was collected from the horse's jugular vein at 15 minutes, 30 minutes, 1, 4, 8, 12, 24 and 48 hours after injection. To purify the gentamicin in serum, 100μL of 20 mM HFBA in DW, 100 μL of 30% trichloroacetic acid and 300 μL of 20 mM heptafluorobutyric acid (HFBA) in acetonitrile (ACN) were added to 500 μL of serum and supernatant was applied to LC-MS/MS after centrifugation. LC-MS/MS-8050 analyzed the level of gentamicin in serum with Electrospray ionization (ESI) and multiple reaction monitoring (MRM) positive mode. Gentamicin C1 was 478 m/z and product ions were 322, 157 m/z. Precursor ion of Gentamicin C1a was 450 m/z and product ions were 322, 160 m/z. Precursor ion of Gentamicin C2 and C2a was 464 m/z and product ions were 322, 160 m/z. The LC column was a C18 and mobile phase composed of 20 mM HFBA in 5% ACN and 20 mM HFBA in 50% ACN. The amount of gentamicin was calculated by adding four components of gentamicin (C1, C1a, C2 and C2a). The pharmacokinetic parameters of gentamicin were calculated by the WinNonlin program. The Cmax of gentamicin in horse serum was 93 ± 17 μg/kg and the Tmax was 0.25 ± 0 hours. The T1/2 was 6.41 ± 2.32 hours and the CLt was 0.05 ± 0.01L/hr/kg. The Vd was shown as 0.44 ± 0.13 L/kg and the MRT was 1.98 ± 0.55 hours. In conclusion, our data provides useful pharmacokinetic parameters for gentamicin in horses following IV injection.

Purpose: This study aimed to evaluate the effectiveness of low-fidelity simulation and actual human practice on the learning outcomes of a peripheral intravenous injection program for nursing students. Methods: Seventy-two third-year nursing students from a university in Seoul were included and divided into two groups; 38 and 34 in the low-fidelity simulation and human practice groups, respectively. The program was conducted from June 19–20, 2024. Data were analyzed using frequency, percentage, mean, standard deviation, χ²-test, independent t-test, and ANCOVA. Results: Both groups showed significant improvements in venipuncture performance, communication skills, empathy, academic performance, and self-efficacy. However, there were no statistically significant differences in these outcomes between both groups. Additionally, post-program learning satisfaction was similarly high in both groups. Conclusion: Low-fidelity simulation is as effective as actual human practice in achieving comparable learning outcomes in a peripheral intravenous injection program for nursing students. With appropriate instructional design, low-fidelity simulation can be a viable alternative to human practice, providing flexibility and accessibility in nursing education. This study underscores the importance of incorporating additional educational modules that enhance emotional and social skills, such as communication and empathy, tailored to the characteristics of individual learners.

Purpose: To develop a tool for measuring peripheral intravenous catheter insertion performance. Methods: This was a cross-sectional descriptive study. Initial items were generated using existing guidelines and tools, and 19 experts assessed content validity. Data were collected from a tertiary hospital in D city from January 17, 2018, to October 20, 2019. The data of 365 nurses were used for principal component analysis with orthogonal rotation. Concurrent validity was confirmed using Pearson’s correlation between the developed tool and the nursing career period. Reliability was confirmed after evaluating internal consistency. Results: Initially, 16 items were generated, but three items were deleted in content validation. A two-factor solution was preferred in exploratory factor analysis and explained 48.2% of the variance. The two factors were named “point of care” and “follow-up care,” respectively. The tool’s reliability is .87. Conclusion: The developed tool was valid and reliable. It is composed of 13 items and can be used quickly and easily. Therefore, it can be utilized for the education and training of novice nurses and the self-reflection of experienced nurses. In addition, it will be useful to review the catheterization process in common clinical settings.

급성 췌장염은 가장 흔한 췌장 질환 중 하나이다. 최근 급성 췌장염의 발생률은 증가하고 있지만 다행하게도 사망률은 감소하고 있다. 급성 췌장염으로 인한 사망은 대부분 초기에 발생하는데 입원 후 7-14일 이내에 발생하며 급격하게 장기 부전을 일으키면서 발생한다. 따라서 급성 췌장염 예후를 호전시키기 위해서는 초기 치료가 가장 중요하다. 초기 치료는 수액 요법, 통증 치료, 국소 및 전신적 합병증 치료, 영양 요법 등이 근간을 이룬다. 수액 치료는 증상 발생 후 첫 12에서 24시간 내에 3-4 L의 lactated Ringer's solution을 대량 공급하는 것이 적절하지만 과다한 수액 공급은 오히려 폐부종, 췌장 주위 저류액 증가, 복부 분획증후군, 패혈증, 사망률 증가 등을 조장할 수 있기에 순환 혈액량을 관찰하면서 수액 투여 용량을 적절하게 조절해야 한다. 중증 급성 췌장염 환자에서 내원 24-48시간 이내 경장 영양법을 시작하면 혈당 조절, 세균 감염 예방, 다발성 장기 부전 및 사망률 감소에 도움이 되며 경공장 또는 경위 영양법 모두 가능하다. 급성 췌장염에서 예방적 항생제는 예후를 호전시키지 못하지만 안정된 감염성 췌장 괴사의 경우에는 항생제 치료가 중요하다.

We investigated the pharmacokinetics of ferulic acid, a potential antioxidant agent, after intravenous (i.v.) bolus administration in rats. To analyze ferulic acid levels in the plasma, bile, urine and tissue samples, we developed an HPLC-based method which was validated for a pharmacokinetic study by suitable criteria. After i.v. bolus administration of ferulic acid, it rapidly disappeared from blood circulation within 15 min. The mean plasma half-lives at α phase (t1/2α) when administered at doses of 2 and 10 mg/ kg were 1.10 and 1.39 min, respectively. The values of t1/2β at the corresponding doses increased 40% (from 5.02 to 7.01 min) with increasing doses. The total body clearance (CLt) values significantly decreased as the ferulic acid dose increased. On the other hand, steady-state volume of distribution (Vdss) values did not show the significant difference with the increase in dose. Of the various tissues, ferulic acid mainly distributed to the liver and kidney after i.v. bolus administration. The ferulic acid concentrations in various tissues at 2 hr after i.v. bolus administration were below 1.0 μg/g tissue. Ferulic acid was excreted in the bile and urine after i.v. bolus administration at the dose of 10 mg/kg. The cumulative amount of ferulic acid in the bile 2 hr after dosage was comparable with the amount excreted in the urine after 72 hr, indicating that i.v. administered ferulic acid was mainly excreted in the both bile and urine. In conclusion, ferulic acid was rapidly cleared from the circulating blood and transferred to tissues such as the liver and kidney after i.v. bolus administration. Moreover, the majority of ferulic acid appears to be excreted in the bile and urine after i.v. bolus administration.

본 연구는 음악요법이 경정맥요로조영 검사로 인한 불안정도와 검사 시 불편감에 미치는 음악요법의 효과를 파악하고자 시도된 비동등성 대조군 사전-사후 실험설계의 유사 실험이다. “음악요법을 받은 군은 음악요법을 받지 않는 군보다 검사 중 불안 점수가 낮을 것이다”는 음악요법 실 시 후 실험군의 불안점수가 대조군의 불안점수와 비교하여 유의한 차이가 있어 채택되었다. “음악요법을 받은 군은 음악요법을 받지 않는 군보다 검사 후 활력징후가 낮을 것이다”는 수축기 혈압, 이완기혈압에 대한 가설은 기각되었지만, 맥박에서는 유의 한 차이가 나타나 부분적으로 채택 되었다. “음악요법을 받은 군은 음악요법을 받지 않는 군보다 주간 적 불편감이 낮을 것이다”는 두 집단 간의 유의한 차이를 보였다. 한편 주관적인 불편 감의 하부요인 중 긴장감 에서만 유의한 차이가 있었으며, 동통, 어지러움, 공포감에서는 유의한 차이가 없었다. 이상의 연구결과로 볼 때 음악요법은 경정맥요로조영 검사 중 환자의 상태불안을 감소시킬 수 있는 유용한 대체검사법이 될 수 있을 것이라고 생각된다.

Proportion of elderly patients is gradually increasing in the republic of Korea. However, intravenous recombinant tissue plasminogen activator (rt-PA) therapy is recently not recommended in elderly acute ischemic stroke patients, although old age is not a proven contraindication to intravenous rt-PA. The purpose of this study was to investigate the safety and prognosis of intravenous thrombolysis in elderly patients.